Clinical Trial

First CORRECT Study of Minimal Residual Disease (MRD) Detection in Colorectal Cancer

Study acronym: MRD
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
The CORRECT - MRD I study will prospectively enroll patients who have undergone complete surgical resection for stage II or III colorectal cancer. Patients will be followed for up to 5 years for recurrence.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-05-01; most recent amendment 2025-07-21.
Status change: Recruiting → Active, Not Recruiting 2025-05-29
Trial Details
NCT Number NCT06398743
Lead Sponsor Exact Sciences Corporation
Collaborators: Fortrea
Conditions Colorectal Cancer
Enrollment 416 participants
Start Date 2023-06-20
Primary Completion 2027-09 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2025-07-24